World Clinical Biomarkers and CDx Summit Japan

Memo

Japan's biomarker and companion diagnostics environment is undergoing significant transformation as regulatory frameworks mature and co-development approaches gain broader institutional backing. While this momentum is opening new pathways for innovation, it also exposes hurdles such as complex reimbursement mechanisms, gaps in CDx implementation infrastructure, and misalignment between global and Japan-specific development timelines. The World Clinical Biomarkers and CDx Summit Japan stands alone as the only event built specifically to address these challenges. Covering every stage of biomarker-led drug development, from early clinical strategy through CDx launch and adoption, the summit unites 80+ senior decision-makers from biopharma, diagnostics, government bodies, and healthcare systems to catalyze collaboration and advance precision medicine. For international companies establishing a presence in Japan and local organizations seeking to expand their impact, this summit delivers the strategic insight, network, and partnerships essential to navigating Japan's complex precision medicine landscape. URLs:Tickets: https://go.evvnt.com/3503933-2?pid=5569Brochure: https://go.evvnt.com/3503933-3?pid=5569 Prices:Drug Developer Pricing - Conference + 1 Engager: USD 0.50,Drug Developer Pricing - Conference Only: USD 0.50,Service Provider Pricing - Conference Only: USD 3399.00 Speakers: Shelley Shaw, Head of Oncology Marketing, Astellas Pharma, Takaharu Hino, Senior Director, Regulatory Strategy and Policy, Oncology, Regulatory Affairs Division, R and D, AstraZeneca, Takaaki Miyazaki, Biomarker Expert, Bayer, Yukinori Ozaki, Breast Medical Oncology, Cancer Institute Hospital, Japan Foundation for Cancer Research, Koichi Tazaki, Senior Director, Daiichi Sankyo, Tsutomu Kawaguchi, Senior Director, Medical, Drug Development and Med Affairs, Onc (Japan), Eli Lilly and Co., Yuji Otsuki, Chief Executive Officer, FerroptoCure, Zach Boyd, Vice President - Global Head of Precision Medicine and Diagnostics, Johnson and Johnson, Min Qing, Director, Oncology Precision Medicine and Diagnostic, Johnson and Johnson, Valerie Mbella, Senior Director and Leader - Global Regulatory Affairs Diagnostics, Johnson and Johnson, Flora Berisha, Executive Director and Head of Global Diagnostic Partnering Development, Johnson and Johnson Innovative Medicine., Stuart Bailey, SVP, Head of Biometrics and Precision Medicine, Merck KGaA, Tomohiko Makino, Deputy Director, Ministry of Health,Labour and Welfare, Tadayoshi Hashimoto, Physician, National Cancer Center Hospital East, Mitsuho Imai, Medical Oncologist, National Cancer Center Hospital East, Ken Shimamura, Diagnostic, Research and Development Lead, Pfizer, Elnaz Jokar, Senior Manager IVD Regulatory Affairs, Regeneron Pharmaceuticals, Kazunori Yamanaka, Lead, Medical Bioinformatics and Translational Research, Takeda Pharmaceutical, Andreas Stange, Senior Vice President, TUV SUD Category: Conferences | Science, Health and Medicine Date and Time: 18th May 2026 at 8:00 am to 20th May 2026 at 6:00 pm Venue details: Hyatt Regency Tokyo, Shinjuku City, Tokyo, 160-0023, Japan